0000905148-20-000880.txt : 20200812
0000905148-20-000880.hdr.sgml : 20200812
20200812210018
ACCESSION NUMBER: 0000905148-20-000880
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200811
FILED AS OF DATE: 20200812
DATE AS OF CHANGE: 20200812
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic Fund II L.P.
CENTRAL INDEX KEY: 0001634632
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 201096834
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic GP II, L.P.
CENTRAL INDEX KEY: 0001729409
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 201096835
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Global Strategic GP II, Ltd.
CENTRAL INDEX KEY: 0001729408
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 201096836
BUSINESS ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 415-522-0100
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOODMAN COREY S
CENTRAL INDEX KEY: 0001278411
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 201096837
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adelman Robert J
CENTRAL INDEX KEY: 0001329161
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39425
FILM NUMBER: 201096838
MAIL ADDRESS:
STREET 1: 1700 OWENS STREET
STREET 2: SUITE 595
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkmate Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001651431
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364813934
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 978-503-2124
MAIL ADDRESS:
STREET 1: 245 MAIN STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
form4.xml
X0306
4
2020-08-11
0001651431
Checkmate Pharmaceuticals, Inc.
CMPI
0001634632
venBio Global Strategic Fund II L.P.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001729409
venBio Global Strategic GP II, L.P.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001729408
venBio Global Strategic GP II, Ltd.
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001278411
GOODMAN COREY S
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
0001329161
Adelman Robert J
1700 OWENS STREET
SUITE 595
SAN FRANCISCO
CA
94158
true
Common Stock
2020-08-11
4
C
0
3473374
A
3473374
D
Common Stock
2020-08-11
4
P
0
200000
15
A
3673374
D
Series A Preferred Stock
2020-08-11
4
C
0
12500000
0
D
Common Stock
1671771
0
D
Series B Preferred Stock
2020-08-11
4
C
0
8753350
0
D
Common Stock
1314165
0
D
Series C Preferred Stock
2020-08-11
4
C
0
3644624
0
D
Common Stock
487438
0
D
The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
venBio Global Strategic Fund II, L.P., by: venBio Global Strategic GP II, L.P., its general partner, by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki, as attorney-in-fact
2020-08-12
venBio Global Strategic GP II, L.P., by: venBio Global Strategic GP II, Ltd., its general partner, by: /s/ David Pezeshki as attorney-in-fact
2020-08-12
venBio Global Strategic GP II, Ltd., by: /s/ David Pezeshki, as attorney-in-fact
2020-08-12
Corey Goodman, by: /s/ David Pezeshki, as attorney-in-fact
2020-08-12
Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact
2020-08-12